# Safety and Biological Activity of TroVax® Vaccine Given With IL-2 in Renal Cell Carcinoma

> **NCT00325507** · PHASE2 · COMPLETED · sponsor: **Oxford BioMedica** · enrollment: 25 (actual)

## Conditions studied

- Carcinoma, Renal Cell

## Interventions

- **BIOLOGICAL:** TroVax
- **DRUG:** IL-2

## Key facts

- **NCT ID:** NCT00325507
- **Lead sponsor:** Oxford BioMedica
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** 2008-07
- **Final completion:** 2008-07
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2020-10-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00325507

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00325507, "Safety and Biological Activity of TroVax® Vaccine Given With IL-2 in Renal Cell Carcinoma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00325507. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*